| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 0 | 2,730 | 60 | 60 | 60 |
| Sales Growth | -100.00% | +4,450.00% | unch | unch | unch |
| Net Income | -3,960 | -920 | 21,490 | -29,920 | -8,480 |
| Net Income Growth | -330.43% | -104.28% | +171.82% | -252.83% | +93.11% |
Traws Pharma Inc (TRAW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Traws Pharma Inc. is involved in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Traws Pharma Inc., formerly known as Onconova Therapeutics Inc., is based in NEWTOWN, Pa.
Fiscal Year End Date: 12/31